Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?

Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$150.11M-3.7%	-$144.74M+3.0%	-$149.28M+20.4%	-$187.6M+14.3%	-$218.86M+27.5%
Depreciation and amortization	$467K-11.0%	$525K-9.0%	$577K-14.9%	$678K-9.0%	$745K-17.6%
Stock-based compensation	$26.93M-2.6%	$27.65M-1.3%	$28M+1.0%	$27.73M-7.4%	$29.95M-9.4%
Net cash from operating activities	-$120.4M+2.4%	-$123.34M+20.1%	-$154.45M+6.8%	-$165.65M+20.0%	-$206.98M-23.5%
Capital expenditures	——	$138K+91.7%	$72K—	——	——
Net cash from investing activities	——	——	——	——	$31.18M-58.8%
Proceeds from issuance of debt	——	——	——	——	——
Net cash from financing activities	——	——	——	——	$65.88M+18,831%
Net increase (decrease) in cash	$168.91M+13.5%	$148.8M+1.0%	$147.32M+778%	-$21.74M+81.2%	-$115.62M-18.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?: Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.